<DOC>
	<DOCNO>NCT01302756</DOCNO>
	<brief_summary>The purpose study determine higher-than usual dos daily folic acid effect rate gestational diabetes mellitus ( GDM ) gestational hypertension pregnant woman determine status folic acid , vitamin B12 , homocysteine vitamin D pregnancy .</brief_summary>
	<brief_title>The Effect High Dose Folic Acid Versus Placebo Rate Gestational Diabetes Gestational Hypertension Pregnant Women</brief_title>
	<detailed_description>Subjects ( DoD beneficiary ) recruit non-diabetic female subject least 18 year age empanel care Nellis Air Force Base . Upon arrival mandatory New Obstetrics ( OB ) Orientation , potential subject offer opportunity participate study . A total 650 subject recruit . After consent HIPAA Authorization obtain , subject Baseline blood pressure , fast glucose , folic acid , vitamin B12 , homocysteine , vitamin D measurement , weight , height , race , ethnicity , parity , vegetarian status record . Subjects write prescription send Clinical Pharmacy randomize via block randomization . After randomization , receive either placebo 4 milligram folic acid ( addition standard care pre-natal vitamin ) pharmacy -- thus investigator subject blind treatment . Group 1 : Placebo plus standard care pre-natal vitamin ( include 1 milligram folic acid ) day duration pregnancy Group 2 : Will take additional 4-milligrams folic acid day duration pregnancy plus standard care pre-natal vitamin ( include 1 milligram folic acid ) The Placebo gelatin capsule fill starch increase risk subject . The pre-natal vitamin dispense MOFH Clinical Pharmacy include 1 milligram folic acid . The folic acid manufacture West Ward Pharmaceutical Corp. Those subject Group 2 take total 5 milligram folic acid ( 1 milligram folic acid contain standard care pre-natal vitamin give additional 4 milligram folic acid part research study ) . The placebo manufacture Green Valley Medical Supply Company . Subjects continue receive routine obstetrics care take prescription duration pregnancy . Per American College Obstetrics Gynecology ( ACOG ) , patient test gestational diabetes either 2nd trimester risk factor prior GDM , age &gt; 34 body mass index &gt; 25 28 week standard risk woman . There unblinded person monitor adverse effect may occur . At 28 week gestation , weight , height , diagnosis GDM , gestational hypertension , pre-eclampsia , post-partum hemorrhage , maternal death record , ask take study medication prescribe ( study show patient recall accurate pill count ) . At delivery , folic acid , B12 , homocysteine , vitamin D measure weight , height , diagnosis GDM , gestational hypertension , pre-eclampsia , post-partum hemorrhage , maternal death , birth weight , shoulder dystocia , neonatal/fetal mortality record , ask take study medication prescribe ( study show patient recall accurate pill count ) . After completion first 200 subject , interim power analysis identify whether trial stop early . At point conclusion study , data de-identified analyzed . A paper write submit scientific journal conclusion study . When subject complete study , Pharmacy de-randomize information send Principal Investigator analysis . If time study , subject decides withdraw study , refer Primary Care Manager initiate standard care treatment . If subject experience fetal demise maternal death , Principal Investigator consult Obstetrics initiate proper clinical care . Folic acid common supplement pregnancy . `` In accordance 21 CFR 312.2 ( b ) ( i-v ) , IND exemption request base follow provision : ( ) The investigation intend report FDA well-controlled study support new indication use intend used support significant change label drug ; ( ii ) If drug undergo investigation lawfully market prescription drug product , investigation intend support significant change advertising product ; ( iii ) The investigation involve route administration dosage level use patient population factor significantly increase risk ( decrease acceptability risk ) associate use drug product ; ( iv ) The investigation conduct compliance requirement institutional review set forth part 56 requirement informed consent set forth part 50 ; ( v ) The investigation conduct compliance requirement ยง312.7 . ''</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes , Gestational</mesh_term>
	<mesh_term>Hypertension , Pregnancy-Induced</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Tricare Insurance Beneficiary ( military insurance ) receive care Nellis AFB Pregnant female ( DoD beneficiary ) least 18 year age Diagnosed diabetic Diagnosed chronic hypertension prior pregnancy Personal family history neural tube defect personal history birth defect Unable communicate NonEnglish speaking Patients know move prior delivery Patients Gastric Bypass surgery Patients know seizure disorder antiseizure medication Patients take folic acid antagonist Patients hypohomocysteine Previously diagnose Methylenetetrahydrofolate reductase ( MTHFR ) mutation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>gestational diabetes</keyword>
	<keyword>gestational hypertension</keyword>
	<keyword>folic acid</keyword>
</DOC>